STOCK TITAN

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals announced that previously disclosed results from the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia have been published. The study showed significant reductions in daily pain and improvements in sleep and fatigue. TNX-102 SL is a non-opioid analgesic and is currently in a Phase 3 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.